| 29.74 0.84 (2.91%) | 09-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.1 |
1-year : | 43.33 |
| Resists | First : | 31.76 |
Second : | 37.1 |
| Pivot price | 29.44  |
|||
| Supports | First : | 29 |
Second : | 27.29 |
| MAs | MA(5) : | 28.52 |
MA(20) : | 29.67 |
| MA(100) : | 30.46 |
MA(250) : | 25.6 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 40.4 |
D(3) : | 25.6 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 35.83 | Low : | 17 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AVBP ] has closed below upper band by 42.8%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.2 - 31.33 | 31.33 - 31.46 |
| Low: | 28.79 - 28.92 | 28.92 - 29.04 |
| Close: | 29.53 - 29.75 | 29.75 - 29.98 |
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Fri, 18 Sep 2026
ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Explosive 57.62% Upside Potential Fuels Investor Interest - directorstalkinterviews.com
Thu, 27 Aug 2026
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case (NASDAQ:AVBP) - Seeking Alpha
Fri, 24 Jul 2026
ArriVent BioPharma, Inc. Revenue Breakdown – NASDAQ:AVBP - TradingView
Tue, 21 Jul 2026
ArriVent BioPharma (AVBP) Edges Lower, Holding Above Key Support as Consolidation Continues - High Dividend Factor - careplusvn.com
Thu, 25 Jun 2026
AVBP Forecast — Price Target — Prediction for 2027 - TradingView
Tue, 26 May 2026
AVBP - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 98.6 (%) |
| Shares Short | 8,230 (K) |
| Shares Short P.Month | 7,670 (K) |
| EPS | -3.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.2 % |
| Return on Equity (ttm) | -53.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -148 (M) |
| Levered Free Cash Flow | -89 (M) |
| PE Ratio | -8.38 |
| PEG Ratio | 0 |
| Price to Book value | 3.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|